

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : A61K 37/02, 37/36	A1	(11) International Publication Number: WO 90/06762 (43) International Publication Date: 28 June 1990 (28.06.90)
(21) International Application Number: PCT/US89/05455 (22) International Filing Date: 1 December 1989 (01.12.89) (30) Priority data: 285,159 16 December 1988 (16.12.88) US (71) Applicant: AMGEN INC. [US/US]; 1840 Dehavilland Drive, Thousand Oaks, CA 91320 (US). (72) Inventors: BOONE, Thomas, C. ; 3913 Elkwood, Newbury Park, CA 91320 (US). KENNEY, William, C. ; 2654 Castillo Circle, Thousand Oaks, CA 91360 (US). (74) Agent: BYRNE, Thomas, E.; Amgen Inc., 1840 Dehavilland Drive, Thousand Oaks, CA 91320 (US).		(81) Designated States: AU, JP. Published <i>With international search report.</i>
(54) Title: STABILIZED HYDROPHOBIC PROTEIN FORMULATIONS (57) Abstract A stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein is disclosed. Also disclosed are associated means and methods for preparing such formulations.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

STABILIZED HYDROPHOBIC PROTEIN FORMULATIONSField of the Invention

5 The present invention is directed to
pharmaceutical formulations containing a protein and to
methods for making and using such formulations. More
particularly, this invention relates to such pharmaceu-
tical formulations having increased stability. The
10 formulations are also very stable during processing.
Formulations are provided for immediate, safe, effective
therapeutic administration to human subjects.

Background of the Invention

15

Granulocyte Colony Stimulating Factor

Granulocyte Colony Stimulating Factor (G-CSF),
in its natural form comprises two forms: a protein
20 having 174 amino acids, and a form having three addi-
tional amino acids. Both forms have five cysteine
residues; four forming two disulfide bonds, and one
free. In its natural form G-CSF is a glycoprotein.
G-CSF supports the growth of predominantly neutrophil
25 colonies in a colony-forming (CFU-GM) assay, and in the
presence of accessory cells, supports the growth of
early erythroid (BFU-E) and pluripotential progenitors
(CFU-GEMM) (granulocytes, erythrocytes, monocytes, and
macrophages). G-CSF is also capable of promoting the
30 differentiation of some myeloid leukemic cell lines
(e.g., HL-60, WEHI-3B-D⁺), fresh myeloid leukemic cells,
and has been reported to enhance the chemotactic peptide
binding on peripheral blood neutrophils. In addition,
G-CSF can significantly increase the ability of
35 neutrophils to kill tumor targets in vitro through
antibody-dependent cellular cytotoxicity (ADCC).

- 2 -

In vivo experiments with recombinant human G-CSF in hamsters indicate a specific action on the neutrophil lineage with increases of three to sixfold in peripheral blood neutrophils.

5 Because of its hydrophobic characteristics, G-CSF is difficult to formulate. Examples of attempts to formulate G-CSF are shown in UK Patent Application GB 2193631. Detergents, such as Tween-80, have been used to maintain G-CSF in a monomeric form and to
10 minimize particulate formation. G-CSF contains five cysteinyl residues, four of which are involved in intrachain disulfide linkage. The free cysteinyl residue is, in general, inaccessible to modification due to folding of the molecule. At elevated temperatures
15 the molecule "breaths" more rapidly and, on occasion, the cysteinyl residues interacts with each other leading to dimer and multimer formation. This phenomenon is enhanced by the presence of a non-ionic surfactant, e.g., Tween-80^m (polyoxyethylene sorbitan monooleate).

20

Interleukin-II

Interleukin II ("IL-2"), a glycoprotein with a molecular weight of approximately 15,000, is a member of
25 a group of proteins, called lymphokines, that control the body's immune response. IL-2 is produced by certain white blood cells, lectin- or antigen-activated T cells, and plays a central role in the body's immune system as a lymphocyte regulating molecule.

30 IL-2 has been reported to enhance thymocyte mitogenesis, to stimulate long-term in vitro growth of activated T-cell clones, to induce cytotoxic T-cell reactivity, to modulate immunological effects on activated B cells and lymphokine activated cells, to
35 induce plaque-forming cell responses in cultures of nude mouse spleen cells, and to regulate production of

- 3 -

gamma interferon. It also augments natural killer cell activity and mediates the recovery of the immune function of lymphocytes in selected immunodeficient states.

5 In order that materials like G-CSF or IL-2 be provided to health care personnel and patients, these materials must be prepared as pharmaceutical compositions. Such compositions must maintain activity for appropriate periods of time, must be acceptable in
10 their own right for easy and rapid administration to humans, and must be readily manufacturable. In many cases pharmaceutical formulations are provided in frozen or in lyophilized form. In these cases, the compositions must be thawed or reconstituted prior to
15 use. The frozen or lyophilized forms are often used to maintain biochemical integrity and the bioactivity of the medicinal agent contained in the compositions under a wide variety of storage conditions. Such lyophilized preparations are reconstituted prior to use by the
20 addition of suitable pharmaceutically acceptable diluent(s), such as sterile water for injection or sterile physiological saline solution, and the like.

Alternatively, the composition can be provided in liquid form appropriate for immediate use. Desirable
25 is a liquid formulation which maintains its activity in long term storage.

Prior formulations of certain hydrophobic proteins lose activity due to formation of dimer and higher order aggregates (macro range) during long-term
30 storage. Other chemical changes, such as deamidation and oxidation may also occur upon storage.

It is an object of the present invention to prepare stable, aggregate-free formulations containing a hydrophobic protein.

35

- 4 -

A further object of the invention is to provide hydrophobic protein formulations with enhanced characteristics.

5 A further object of the invention is to provide hydrophobic protein formulations with higher G-CSF concentrations.

10 A still further object of the invention is to provide formulations containing proteins wherein no component is derived from animals, e.g., natural albumin, thus avoiding possible contamination of the formulation with impurities.

15 Other objects, features and characteristics of the present invention will become more apparent upon consideration of the following description and the appended claims.

Summary of the Invention

20 Objects of this invention are accomplished by a pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a pharmaceutically effective amount of a hydrophobic protein stable at acid pH, and acid, wherein said formulation has an acidic pH, and advantageously a low
25 conductivity, i.e. less than about 1000 μ mhos/cm. Advantageously the pH of the formulation is about 2.75-4.0, and in a preferred embodiment no buffer is present. The formulation has a purity level which is pharmaceutically acceptable. The formulation is capable
30 of undergoing processing and storage with substantially no dimer or higher order aggregate formation. The invention also comprises a method of stabilizing a formulation comprising the step of combining the protein with acid, advantageously without the addition of any
35 salt, to make a pharmaceutically acceptable formulation having an acidic pH and advantageously an ionic strength

- 5 -

of less than 1000 μ mhos/cm. Optionally, a tonicity modifier is added.

Description of the Figures

5

Figure 1 shows G-CSF prepared at various pH values and run on a 15% gel after reduction of thiol groups.

10

Figure 2 shows G-CSF prepared at various pH values and run on a 15% non-reducing gel.

Detailed Description of the Invention

15

The present invention is based upon the discovery that at acidic pH values a specific pharmaceutically acceptable formulation of a protein maintains the activity of the protein, and inhibits undesirable reactions that the protein undergoes during processing, reconstitution, and storage. As used herein, the term "processing" includes filtration and filling into vials. The invention is thus directed to such formulations, and to all associated formulations and to means for effectively stabilizing such proteins.

20

25

As used herein, the term "hydrophobic proteins stable at acidic pH" denotes proteins produced, for example, from natural source extraction and purification, or by recombinant cell culture systems. The term includes biologically active granulocyte colony stimulating factor (G-CSF), Interleukin-II (IL-2), and other hydrophobic proteins stable at acidic pH, and their equivalents; e.g., differing in one or more amino acid(s) in the overall sequence. Further, the term as used in this application is intended to cover substitution, deletion and insertion of amino acid variants, or post translational modifications. Various forms of

30

35

- 6 -

G-CSF and methods of production are disclosed in WO 8701132 hereby incorporated by reference. Various forms of IL-2 and methods of production are disclosed in WO 8500817 and U.S. Ser. No. 214,998 filed July 5, 1988, both hereby incorporated by reference.

The formulation of the subject invention comprises:

- a) a pharmaceutically acceptable amount of a hydrophobic protein stable at acidic pH; and
 - b) acid,
- wherein said formulation has an acidic pH, advantageously no buffer, and advantageously a conductivity of less than 1000 μ mhos/cm.

In a preferred embodiment relating to G-CSF, the G-CSF formulation of the subject invention comprises:

- a) G-CSF at up to 2 mg/ml; and
 - b) hydrochloric acid; and
 - c) mannitol as a tonicity modifier,
- wherein the pH is 3.2-3.3 and the conductivity of the formulation is less than 500 μ mhos/cm.

In the composition of the subject invention, high concentrations of G-CSF (e.g. 1-5 mg/ml) are achievable. The subject formulation eliminates the need for Tween-80. A low conductivity is very advantageous in the subject invention. The pH of the subject formulation is advantageously low.

In general, the formulations of the subject invention may contain other components in amounts preferably not detracting from the preparation of stable forms and in amounts suitable for effective, safe pharmaceutical administration.

- 7 -

Suitable pH ranges for the preparation of the formulations hereof are from about 2.75 to about 4, advantageously about 3.0 to about 3.7, most advantageously 3.2 to 3.3. The formulation pH advantageously should be less than 4 to reduce aggregate formation. pH values are advantageously above 2.75 since values below 2.75 result in substantial peptide bond cleavage. If necessary, the pH is adjusted with acid such as dilute hydrochloric, nitric, phosphoric, or sulfuric acid solutions. In one embodiment, the total acid content is low, i.e. less than about 5 mM to keep the conductivity of the formulation low. In a preferred embodiment no salt (compound derived from an acid by replacing hydrogen with a metal) other than that which is a trace residual by-product of the purification process, is present in the formulation (this embodiment is referred to herein as having no salt).

In a preferred embodiment, no buffer is present other than the protein of interest itself and trace residual by-product of the purification process (this embodiment is referred to herein as having no buffer). The preferred buffer when a buffer is used, is a carboxylic acid buffer. Alternatively, citric, lactic or tartaric acid buffer is used at about 1 mM. A buffer concentration greater than or equal to 0 and less than 2 mM is preferred, most advantageously 1 mM. The buffer concentration is kept low to keep the conductivity of the formulation low. In this concentration range of buffer, minimal aggregation occurs.

The conductivity of the formulations of the subject invention should be less than 1000 μ mhos/cm., although at pH values between about 2.75 and 3 the formulation conductivity is optionally higher. Advantageously the conductivity is less than 700 μ mhos/cm, and most advantageously less than 500 μ mhos/cm. In a preferred embodiment the

- 8 -

conductivity is less than 200 μ mhos/cm. The conductivity is adjusted by methods such as diafiltration.

Advantageously, formulations of the subject invention are isotonic with the blood of the recipient. A formulation containing about 4-6% (w/v), advantageously 5% (w/v), mannitol as a non-ionic tonicity modifier results in isotonic solution suitable for intravenous injection. The tonicity modifier also acts to stabilize the formulation. As an alternative to mannitol, other sugars or sugar alcohols are used, such as sucrose, maltose, fructose, lactose and the like.

The formulation of the subject invention may optionally include one of several types of non-ionic surfactants, such as Tween 80. In a preferred embodiment no surfactant is present in the formulation.

Also comprehended by the invention are formulations comprising pharmaceutically effective amounts of protein together with suitable diluents, adjuvants and/or carriers. Other pharmaceutically acceptable excipients well known to those skilled in the art may also form a part of the subject compositions. These include, for example, various bulking agents, additional buffering agents, chelating agents, antioxidants, preservatives, cosolvents, and the like; specific examples of these could include, trimethylamine salts ("Tris buffer"), and EDTA. In one embodiment, more than one type of protein, e.g. IL-3 and G-CSF, are included in the formulation. In another embodiment, no proteins other than the one protein of interest are part of the formulation.

A "pharmaceutically effective amount" of protein residue refers to that amount which provides therapeutic effect in various administration regimens. Such amounts are readily determined by those skilled in the art. The amount of active ingredient will depend upon the severity of the condition being treated, the

- 9 -

route of administration, etc. The compositions hereof may be prepared containing amounts of protein of at least about 0.1 mg/ml, upwards of about 5 mg/ml. For G-CSF, preferably from about 0.5 mg/ml to about 2 mg/ml. For use of these compositions in administration to human patients suffering from chronic neutropenia, for example, these compositions may contain from about 0.5 mg/ml to about 4 mg/ml, corresponding to the currently contemplated dosage rate for such treatment. For IL-2, the compositions are prepared containing from about 0.1 to 1.0 mg/ml.

The formulations are prepared in general by combining the components using generally available pharmaceutical combining techniques, known per se. A particular method for preparing a pharmaceutical formulation hereof comprises employing the protein purified according to any standard protein purification scheme.

20 EXPERIMENTAL

A. Formulation preparation

The pH of G-CSF solution at about 5 mg/ml is adjusted to 3.25 ± 0.1 with 0.5 N hydrochloric acid and this solution is diafiltered against water for injection adjusted to pH 3.25 with hydrochloric acid (about 0.56 mM HCl). Diafiltration is continued until the conductivity of the permeate is less than 760 μ mhos/cm. This solution is combined with 20% mannitol, and water for injection to obtain a final concentration of 1 mg G-CSF/ml and 5% (w/v) mannitol. If necessary, the pH is adjusted to 3.25 with hydrochloric acid or sodium hydroxide solutions. The solution is then passed through a 0.2 μ filter.

- 10 -

B. Analytical Methods

The analytical methods used are described in the following articles hereby incorporated by reference:

5

SDS-PAGE: Lammler, U.K.

Nature 227, 680-685(1970)

HP-SEC: Watson, E. & Kenney, W.

J. Chromatog. 436, 289-298 (1988)

10

Results

Figure 1 shows a 15% SDS polyacrylamide gel after reduction of protein thiol groups. The formulations of samples A-H were stored for 2 weeks at 52°C. The G-CSF was formulated at 1 mg/ml with 5% (w/v) mannitol.

	<u>Sample</u>	<u>pH</u>
	A	pH 4.2
20	B	pH 3.5
	C	pH 3.23
	D	pH 3.0
	E	pH 2.75
	F	pH 2.5
25	G	pH 2.0
	H	pH 3.0 + 10mM NaCl
	I	pH 3.23 stored at 4°C

Figure 2 shows a 15% non-reducing SDS polyacrylamide gel. Samples were prepared as in the case of the reducing gel (i.e., 2 weeks at 52°C).

Note: (1) the amount of aggregate decreasing with decreasing pH:

A = pH 4.2
B = pH 3.5
C = pH 3.23;

35

- 11 -

(2) the increasing lower mol. wt. bands due to hydrolysis in E, F, G:

E = pH 2.75

F = pH 2.5

G = pH 2.0;

(3) the higher ionic strength yielding more aggregate:

D = 0 NaCl, pH 3.0

H = 10 mM NaCl, pH 3.0.

Table 1

Percent G-CSF Remaining as Monomer
after Incubation for 2 Weeks at 42°C or 52°C

	Sample	pH	% monomer ¹	
			42°C	52°C
	A	4.2	>99	39.6
20	B	3.5	>99	93.8
	C	3.23	>99	97.6
	D	3.0	>99	98.5
	E	2.75	>99	98.5
	F	2.5	>99	98.3
25	G	2.0	98.6	87.1
	H	3.0 + 10 mM NaCl	>99	88.6

¹Starting sample > 99% monomer when stored at 4°C.

30 The results in Table 1 as determined by HP-SEC (Watson, Kenny J. Chromatog. 436, 289-298 (1988)), show that the least amount of aggregate formation was in samples C,D, E & F, which corresponds to a pH range of 3.2-2.50. Further, the presence of salt increased the
35 amount of aggregate (compare D to H). Except for A, & G, little change occurred with incubation at 42°.

- 12 -

Examining the results of Figures 1 and 2 and Table 1 together, the most advantageous formulation pH values were those of samples C, D and E, i.e. about pH 2.75-3.23.

5 Data for IL-2 was substantially the same as that for G-CSF, i.e. the IL-2 was most stable when formulated at a pH of 3-4, and at an conductivity of less than 1000 $\mu\text{mhos/cm}$, advantageously less than 700 $\mu\text{mhos/cm}$, and more advantageously less than 10 500 $\mu\text{mhos/cm}$.

* * *

15 While the invention has been described in what is considered to be its preferred embodiments, it is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent formulations included within the spirit and scope of the appended claims, which scope is to be 20 accorded the broadest interpretation so as to encompass all such modifications and equivalent formulations.

25

30

35

- 13 -

WHAT IS CLAIMED:

1. A stabilized pharmaceutically acceptable formulation comprising:
 - a) a pharmaceutically acceptable amount of a hydrophobic protein stable at acidic pH; and
 - b) acid;wherein said formulation has a pH of 3.0-3.7 and a conductivity of less than 1000 $\mu\text{mhos/cm}$.
2. A formulation as in Claim 1 having a pH of about 3.2-3.3.
3. A formulation as in Claim 1 wherein the acid is hydrochloric acid.
4. A formulation as in Claim 1 further comprising a pharmaceutically acceptable tonicity modifier.
5. A formulation as in Claim 4 wherein the tonicity modifier is mannitol.
6. A formulation as in Claim 5 wherein the mannitol is about 5% (w/v) of the formulation.
7. A formulation as in Claim 1 wherein said protein is selected from the group consisting of G-CSF and IL-2.
8. A formulation as in Claim 1 additionally comprising a pharmaceutically acceptable diluent, adjuvant or carrier.
9. A formulation as in Claim 1 which is substantially dimer free.

- 14 -

10. A formulation as in Claim 1 additionally comprising a nonionic surfactant.

5 11. A formulation as in Claim 1 further comprising a buffer.

12. A formulation as in Claim 1 wherein said hydrophobic protein is G-CSF present at a concentration of 0.5-2 mg/ml, and wherein said formulation has a pH of
10 3.2-3.3 and a conductivity of less than 200 μ mhos/cm.

13. A method of stabilizing a formulation of a hydrophobic protein stable at acidic pH comprising the step of combining a pharmaceutically acceptable amount
15 of said protein with acid; wherein said formulation has a pH of 3.0-3.7 , a conductivity of less than 1000 μ mhos/cm, and is pharmaceutically acceptable.

14. A method as in Claim 13 wherein said
20 combining step also includes adding a pharmaceutically acceptable tonicity modifier.

15. A method as in Claim 13 wherein said combining step includes adding hydrochloric acid.
25

16. A method as in Claim 13 wherein said formulation has a pH of 3.2-3.3.

17. A method as in Claim 13 wherein said
30 combining step does not include adding salt.

18. A method as in Claim 14 wherein said tonicity modifier is mannitol.

35

- 15 -

19. A method as in Claim 13 wherein said protein is selected from the group consisting of G-CSF and IL-2.

5 20. A method as in Claim 18 wherein the mannitol is about 5% (w/v) of the formulation.

21. A stabilized pharmaceutically acceptable salt formulation comprising;

10 a) a pharmaceutically acceptable amount of a hydrophobic protein stable at acidic pH; and

b) acid;

wherein said formulation has an acidic pH and no buffer.

15

22. A formulation as in Claim 21 having a pH of about 2.75-4.

23. A formulation as in Claim 21 further comprising a pharmaceutically acceptable tonicity modifier.

20

24. A formulation as in Claim 21 having no surfactant present.

25



25. A formulation as in Claim 21 having a conductivity of less than 1000 μ mhos/cm.

26. A formulation as in Claim 21 wherein said protein is selected from the group consisting of G-CSF and IL-2.

30

35


1 / 2



A B C D E F G H I

FIG. I

2 / 2



A B C D E F G H I

FIG.2

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US89/05455

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5) A61K 37/02,37/36

U.S. CL. 424/85.1,85.2,514/2,8,12,21

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

U.S.

424/85.1,85.2; 514/2,8,12,21,970; 530/351,395;
435/69.5,69.52,69.6

Documentation Searched other than Minimum Documentation
to the extent that such Documents are Included in the Fields Searched *

Computer Search of Dialog and CAS, files 5,155,350,351,CA

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *

Citation of Document, ** with indication, where appropriate, of the relevant passage

X	US, A, 4,645,830, (YASUSHI), 24 February 1987 see col's. 2-3 and claims.	
X Y	US, A, 4,675,184, (HASEGAWA), 23 June 1987 see col's. 1-2	
X Y	US, A, 4,647,454, (CYMBALISTA), 3 March see col 1	
Y,P	US, A, 4,810,643, (SOUZA), 7 March 1989	
Y,P	US, A, 4,833,127, (ONO), 23 March 1989 see col's 11,13-14	1-26
Y	Journal of Parenteral Drug Association, Issued 1980, "Review of Excipients and PH's for Parenteral Pro- ducts Used in the United States", (WANG), pages 452- 462, see all.	1-26
Y	Journal of Parenteral Science and Technology, vol 42-supplement, Issued 1988, "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers, "(WANG), pages S3-26, see all.	1-26

* Special categories of cited documents: **

"A" document defining the general state of the art which is not
considered to be of particular relevance

"E" earlier document but published on or after the international
filing date

"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or
other means

"P" document published prior to the international filing date but
later than the priority date claimed

"T" later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention

"X" document of particular relevance; the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step

"Y" document of particular relevance; the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

09-March 1990

11 APR 1990

International Searching Authority

Signature of Authorized Officer

ISA/US

Garnette D. Draper

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	US, A, 4,623,717, (FERNANDES) 18 November 1986.	1-26
A	Chemical Abstracts, vol 108, Issued March 1988, "Effect of pH on Binding and Dissociation of Colony- Stimulating Factor" (WAHEED), Abstract No. 110688m, Proc. Soc. Exp. Biol. Med. 1988, 187(1), pages 69-75.	1-26

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter^{1,2} not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out^{1,3}, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

I Claims 1-26 drawn to compositions containing distinct species wherein one specie is G-CSF.

II Claims 1-26 drawn to compositions containing distinct specie wherein one specie is IL-2. (See Attachment)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. Telephone Practice

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort, justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

ATTACHMENT TO PCT/ISA/210, PART VI

Detailed Reasons For Holding Lack of Unity of Invention:

The invention as defined by Group I, claims 1-26 is drawn to a stable protein composition containing different and distinct protein specie and methods of preparing such wherein the specie are:

- a) G-CSF
- b) IL-2

PCT Rule 13.2 permits claims to a (one) product; a (one) method of making the product; and to a (one) method of using said product. The specie of G-CSF and the specie of IL-2 represent two distinct and different protein, and there are no provisions in Rule 13.2 for claims covering multiple products.